↓ Skip to main content

What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis

Overview of attention for article published in Frontiers in immunology, April 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
6 Dimensions

Readers on

mendeley
19 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
What Is Long-Term Survival and Which First-Line Immunotherapy Brings Long-Term Survival for Advanced Wild-Type Non-Small Cell Lung Cancer: A Network Meta-Analysis Based on Integrated Analysis
Published in
Frontiers in immunology, April 2022
DOI 10.3389/fimmu.2022.764643
Pubmed ID
Authors

Xue Zhang, Qian Xu, Xuejun Yu, Miao Huang, Song Li, Lei Sheng, Xin Dai, Kai Huang, Jian Wang, Lian Liu

X Demographics

X Demographics

The data shown below were collected from the profile of 1 X user who shared this research output. Click here to find out more about how the information was compiled.
As of 1 July 2024, you may notice a temporary increase in the numbers of X profiles with Unknown location. Click here to learn more.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 19 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 19 100%

Demographic breakdown

Readers by professional status Count As %
Researcher 3 16%
Other 2 11%
Student > Master 2 11%
Lecturer 1 5%
Student > Ph. D. Student 1 5%
Other 3 16%
Unknown 7 37%
Readers by discipline Count As %
Medicine and Dentistry 8 42%
Pharmacology, Toxicology and Pharmaceutical Science 1 5%
Economics, Econometrics and Finance 1 5%
Computer Science 1 5%
Unknown 8 42%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 05 April 2022.
All research outputs
#23,214,800
of 25,872,466 outputs
Outputs from Frontiers in immunology
#28,086
of 32,522 outputs
Outputs of similar age
#384,418
of 451,939 outputs
Outputs of similar age from Frontiers in immunology
#1,489
of 1,656 outputs
Altmetric has tracked 25,872,466 research outputs across all sources so far. This one is in the 1st percentile – i.e., 1% of other outputs scored the same or lower than it.
So far Altmetric has tracked 32,522 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 8.5. This one is in the 1st percentile – i.e., 1% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 451,939 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 1,656 others from the same source and published within six weeks on either side of this one. This one is in the 1st percentile – i.e., 1% of its contemporaries scored the same or lower than it.